Antibiotics: A Complete Clinical Guide for Interns

You are three days into internship. A febrile patient. A waiting nurse. The consultant is busy. You need to make a call. This guide gives you the framework to think clearly, choose appropriately, and document correctly — every time.

1. The Basics You Cannot Skip

Antibiotics are one of the most commonly prescribed — and most commonly misused — drug classes in clinical medicine. Before you learn the drugs, understand the framework.

Bactericidal vs Bacteriostatic

This distinction matters when your patient is immunocompromised or critically ill.

Clinical rule: For bacterial endocarditis and CNS infections, never use bacteriostatic agents as monotherapy. The blood-brain barrier and avascular valve vegetations require bactericidal drugs that kill independently of immune function.

Time-dependent vs Concentration-dependent Killing

This determines how you dose. Understanding this prevents underdosing failures and toxicity from overdosing.

This is why aminoglycosides are given as a single daily dose (maximise peak) while beta-lactams are given every 6–8 hours (keep above MIC). Extended infusions of piperacillin-tazobactam over 4 hours exploit this same principle.

2. Antibiotic Classes, Mechanisms & Key Drugs

Beta-Lactams

Mechanism: Inhibit cell wall synthesis by binding to Penicillin-Binding Proteins (PBPs), blocking peptidoglycan cross-linking. Bactericidal. Works only on actively dividing bacteria.

The beta-lactam ring is the active core. Bacteria resist these by producing beta-lactamases (enzymes that hydrolyse the ring). Beta-lactamase inhibitors (clavulanate, tazobactam, sulbactam, avibactam) are added to protect the drug — e.g., amoxicillin-clavulanate, piperacillin-tazobactam.

Glycopeptides

Mechanism: Bind D-Ala-D-Ala terminus of peptidoglycan precursors, blocking cell wall synthesis. Bactericidal. Gram-positive only — too large to penetrate Gram-negative outer membrane.

• Vancomycin: IV for systemic MRSA and severe Gram-positive infections. Oral vancomycin for C. difficile only — does NOT work systemically. Monitor trough/AUC levels. Nephrotoxic.
• Teicoplanin: Once-daily dosing after loading. Less nephrotoxic than vancomycin.

Aminoglycosides

Mechanism: Bind 30S ribosomal subunit → misreading of mRNA → aberrant proteins → cell death. Concentration-dependent killing. Single daily dosing is standard — reduces toxicity. Synergistic with beta-lactams for serious Gram-positive infections (endocarditis). Nephrotoxic and ototoxic — monitor levels, avoid in renal impairment.

Key drugs: Gentamicin, Amikacin, Tobramycin.

Fluoroquinolones

Mechanism: Inhibit DNA gyrase (Gram-negatives) and topoisomerase IV (Gram-positives), preventing DNA supercoiling. Bactericidal. Concentration-dependent.

Fluoroquinolone caution: Avoid in pregnancy, children under 18, and patients with tendon pathology (Achilles tendon rupture risk). Resistance is rising — check local antibiogram before empirical use for UTI.

Macrolides

Mechanism: Bind 50S ribosomal subunit, blocking peptide elongation. Bacteriostatic. Excellent tissue and intracellular penetration — key for atypical organisms. Key drugs: Azithromycin (once-daily, long half-life), Clarithromycin (H. pylori, MAC), Erythromycin (oldest, most GI side effects). Primary uses: atypical pneumonia (Mycoplasma, Legionella, Chlamydophila), pertussis, STIs, add-on to beta-lactam in CAP.

Tetracyclines

Mechanism: Bind 30S ribosomal subunit. Bacteriostatic. Excellent intracellular penetration. Key drug: Doxycycline. Uses: atypical pneumonia, Lyme disease, rickettsial infections, community MRSA skin infections, acne, malaria prophylaxis. Avoid in pregnancy and children under 8.

Metronidazole

Mechanism: Reduced intracellularly to reactive intermediates that damage DNA. Bactericidal. Active only in anaerobic/microaerophilic conditions. Uses: anaerobic infections (intra-abdominal, dental abscesses), C. difficile mild disease, H. pylori eradication, Trichomonas, Giardia. Excellent oral bioavailability (~100%) — oral equals IV in most situations. Avoid alcohol (disulfiram-like reaction).

TMP-SMX (Co-trimoxazole)

Mechanism: Sequential blockade of folate synthesis — synergistic, bactericidal. Uses: UTI, community MRSA skin infections, PCP prophylaxis/treatment, Toxoplasma, Nocardia, Stenotrophomonas. Avoid in 1st trimester (folate antagonism) and 3rd trimester (kernicterus risk). Dose-adjust in renal impairment.

3. Gram-Positive vs Gram-Negative Coverage

Key Gram-Positive Organisms

Key Gram-Negative Organisms

4. Empirical Antibiotic Selection by Infection Site

Empirical therapy means treating before cultures are available, based on the most likely pathogens for that infection site. The goal is to cover the most dangerous likely organism, not every possible organism.

Community-Acquired Pneumonia (CAP) — IDSA/ATS 2019, NICE NG138

Organisms: S. pneumoniae (most common), Haemophilus, atypicals (Mycoplasma, Legionella, Chlamydophila), Staph aureus post-influenza.

• Mild (outpatient): Amoxicillin 500mg–1g TDS PO OR Doxycycline 100mg BD. Duration: 5 days.
• Moderate (ward): Amoxicillin-clavulanate 1.2g IV TDS + Clarithromycin 500mg BD for atypical cover. OR Ceftriaxone 1–2g IV OD + macrolide.
• Severe (ICU): Piperacillin-tazobactam 4.5g IV TDS + Levofloxacin 500mg IV OD. Add Vancomycin if post-influenza or MRSA risk. Duration: 7–10 days.
• Scoring: Use CURB-65 for admission decision — see the MedDraftPro CURB-65 Calculator.

Urinary Tract Infections (UTI) — IDSA 2025, NICE NG109

Organisms: E. coli (80%), Klebsiella, Proteus, Staphylococcus saprophyticus (young women), Enterococcus.

• Uncomplicated UTI: Nitrofurantoin 100mg MR BD × 5 days OR Trimethoprim 200mg BD × 7 days.
• Pyelonephritis (oral): Ciprofloxacin 500mg BD × 7 days OR Cefuroxime 500mg BD × 7–10 days.
• Pyelonephritis (IV): Ceftriaxone 1g IV OD. Step down to oral once afebrile 48h.
• Urosepsis/cUTI: Piperacillin-tazobactam 4.5g IV TDS OR Meropenem 1g IV TDS if ESBL risk.
• Note: Nitrofurantoin — DO NOT use for pyelonephritis (poor tissue penetration). Fluoroquinolones — avoid first-line if local E. coli resistance >20%.

Bacterial Meningitis — ESCMID Guidelines

Organisms: S. pneumoniae, N. meningitidis, Listeria (age >50, immunocompromised), H. influenzae.

• Empirical (adult): Ceftriaxone 2g IV BD + Vancomycin 15–20mg/kg IV TDS. Add Ampicillin 2g IV 4-hourly if age >50 (Listeria coverage).
• Steroids: Dexamethasone 0.15mg/kg IV QDS × 4 days — start BEFORE or WITH first antibiotic. Reduces mortality in pneumococcal meningitis.
• Duration: S. pneumoniae 10–14 days · N. meningitidis 7 days · Listeria 21 days.
• Critical: Do NOT delay antibiotics for LP if CT required. Start antibiotics → CT → LP. Time to antibiotics is the strongest predictor of outcome.

Sepsis / Septic Shock — Surviving Sepsis Campaign 2021

• Rule #1: Antibiotics within 1 hour of recognising septic shock. 3 hours for sepsis without shock. Draw cultures first, then treat — do not delay antibiotics waiting for results.
• Source unknown: Piperacillin-tazobactam 4.5g IV TDS OR Meropenem 1g IV TDS if ESBL/MDR risk. Add Vancomycin if MRSA risk.
• Intra-abdominal source: Pip-Tazo OR Meropenem + Metronidazole for anaerobic coverage. Source control is as important as antibiotics.
• De-escalation: Reassess at 48–72h. Narrow spectrum based on culture results.

Skin & Soft Tissue Infections (SSTI)

• Cellulitis (non-purulent): Amoxicillin-clavulanate 625mg TDS PO OR Cefalexin 500mg QDS. IV: Ceftriaxone 1g IV OD.
• Purulent/Abscess: MRSA must be covered. TMP-SMX DS BD OR Doxycycline 100mg BD. IV: Vancomycin. Drainage is definitive — antibiotics alone insufficient for abscess.
• Necrotising fasciitis: SURGICAL EMERGENCY. Antibiotics: Meropenem + Vancomycin + Clindamycin (clindamycin inhibits toxin production). Immediate surgical debridement — mortality rises with every hour of delay.
• Diabetic foot: Amoxicillin-clavulanate mild; Pip-Tazo moderate/severe. Add Vancomycin if MRSA risk or systemic sepsis.

Intra-Abdominal Infections

• Community-acquired mild: Amoxicillin-clavulanate IV OR Ceftriaxone + Metronidazole.
• Moderate–severe: Piperacillin-tazobactam 4.5g IV TDS.
• Healthcare-associated/ESBL risk: Meropenem 1g IV TDS.
• Key rule: Antibiotics are adjunct — source control (drainage, surgery) is the definitive treatment for peritonitis and abscesses.

5. Antibiotic Resistance: What Every Intern Must Know

Resistance is not a future problem. You will encounter it in your first week.

Four Core Resistance Mechanisms

MDR Organisms and Treatment

AmpC trap for interns: Enterobacter cloacae, Citrobacter freundii, and Serratia (the ESCPM group) have inducible chromosomal AmpC beta-lactamases. They may test susceptible to 3rd gen cephalosporins in vitro, but resistance can emerge during treatment. For serious infections, use cefepime (4th gen) or carbapenems — not ceftriaxone, even if the sensitivity report says sensitive.

6. Antibiotic Stewardship: Your Professional Responsibility

Stewardship is not bureaucracy. It is the discipline of prescribing well. Every antibiotic course you start has consequences

The 5 D’s of Antimicrobial Stewardship

• Right Drug — Narrowest effective spectrum for the likely pathogen
• Right Dose — Adjusted for weight, renal and hepatic function
• Drug Route — Oral when bioavailability allows; IV is not the default
• Duration — Shortest course that achieves cure
• De-escalation — Narrow spectrum once cultures are available

The 48–72 Hour Antibiotic Time-Out

At 48–72 hours, revisit every antibiotic prescription. Ask: (1) Do cultures confirm an infection requiring antibiotics? (2) Is the drug covering the identified organism? (3) Can I narrow the spectrum? (4) Can I switch IV to oral? (5) What is my planned stop date?

A 2025 multicentre study (67 hospitals, n=37,000) showed de-escalation from broad-spectrum antibiotics in community-onset sepsis patients without MDR risk factors resulted in similar 90-day mortality, fewer antibiotic days, and shorter hospitalisation compared to continuation of broad-spectrum therapy.

IV to Oral Switch

IV antibiotics do not equal better antibiotics. Many conditions can be managed with oral agents that have excellent bioavailability — fluoroquinolones, metronidazole, TMP-SMX, linezolid, clindamycin, amoxicillin-clavulanate all achieve near-100% oral bioavailability. Switch to oral when: patient is clinically improving, afebrile for 24–48h, can tolerate oral, and a suitable oral agent is available.

7. Special Clinical Scenarios

Penicillin Allergy

Most reported penicillin allergies are not true allergies. Only 1–10% of patients reporting penicillin allergy will have a positive skin test. Cross-reactivity between penicillins and cephalosporins is low (~1–2%). Mild allergy (rash only): cephalosporins generally safe. Severe allergy (anaphylaxis, angioedema): use carbapenem or alternative class. Aztreonam is safe in true penicillin allergy. Consider allergy de-labelling in patients with historical documentation.

Renal Impairment

Dose-adjust: aminoglycosides, vancomycin, carbapenems, fluoroquinolones, TMP-SMX. No adjustment needed: clindamycin, moxifloxacin, linezolid, metronidazole, azithromycin (hepatically cleared). Calculate CrCl (Cockcroft-Gault) before prescribing — do not rely on serum creatinine alone in the elderly. Use the MedDraftPro Creatinine Clearance Calculator.

Pregnancy

Hepatic Failure

Dose-adjust or avoid: metronidazole, clindamycin, moxifloxacin, chloramphenicol, linezolid. Generally safe: beta-lactams, aminoglycosides, vancomycin (renally cleared).

Neutropenic Fever (Febrile Neutropenia)

ANC <500 cells/μL + temperature ≥38.3°C. Start antibiotics within 60 minutes of blood cultures. Empirical: Piperacillin-tazobactam OR Cefepime IV. Add Vancomycin if haemodynamically unstable, suspected catheter-related infection, or skin/soft tissue source. Add Meropenem if known ESBL colonisation. Antifungal coverage (caspofungin/voriconazole) if fever persists beyond 72–96h without source.

Documentation tip: Every antibiotic prescription in notes should have: indication (provisional diagnosis), culture sent (yes/no), drug/dose/route/frequency, intended duration, review date at 48–72h.

References

1. IDSA 2024 Guidance on Treatment of Antimicrobial Resistant Gram-Negative Infections. Version 4.0, December 2023.
2. IDSA 2025 Guideline Update on Complicated Urinary Tract Infections.
3. Evans L et al. Surviving Sepsis Campaign: International Guidelines 2021. Intensive Care Med. 2021;47(11):1181–1247.
4. Guidelines for Antibiotic Prescription in the ICU. PMC6734471. Indian Journal of Critical Care Medicine. 2019.
5. Walia K et al. Antimicrobial Stewardship – StatPearls. NCBI NBK572068. Updated 2023.
6. Study Supports De-escalation of Broad-Spectrum Antibiotics in Certain Sepsis Patients. CIDRAP. December 2025.
7. WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2024.
8. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases. 9th Edition. Elsevier. 2020.

Medical Disclaimer: This article is written for educational purposes for medical professionals and students. It does not replace clinical judgment, local antibiograms, or institutional guidelines. Always consult current local resistance data, your hospital formulary, and senior clinical guidance when prescribing antibiotics.

Dr. S. Biswas
MBBS · Practicing Physician · Founder, MedDraftPro
All clinical content on MedDraftPro is written and reviewed by qualified physicians. Dr. S. Biswas is a practicing MBBS physician and the founder of MedDraftPro — a free AI-powered clinical documentation and medical calculator platform built to support doctors and medical students in clinical practice.

✓ Medically reviewed content · References verified against current guidelines